Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 4/20 | 0.51 |
| ▸ | MAOA | P21397 | 3/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17037350 | 0.95 | KMT2A (0.55) | KMT2ADRD2DRD4DRD3MAOB | |
| SCHEMBL10235894 | 0.92 | PPARA (0.55) | KMT2ADRD2DRD4DRD3BCHE | |
| SCHEMBL10235877 | 0.92 | PPARA (0.58) | KMT2ADRD2DRD4DRD3BCHE | |
| SCHEMBL4568905 | 0.91 | KMT2A (0.54) | KMT2AMAOBMAOAALOX5PPARG | |
| SCHEMBL4568878 | 0.88 | PPARA (0.58) | DRD2DRD4DRD3MAOBMAOA | |
| SCHEMBL10235885 | 0.88 | KMT2A (0.54) | KMT2ABCHEPPARGPPARAFFAR1 | |
| SCHEMBL4568938 | 0.84 | MAOB (0.69) | KMT2AMAOBMAOABCHEALOX5 | |
| SCHEMBL10796629 | 0.83 | KMT2A (0.61) | KMT2ADRD2DRD4LTA4HGPBAR1 | |
| SCHEMBL10235898 | 0.83 | CYP2D6 (0.54) | KMT2APPARGPPARA | |
| SCHEMBL4568874 | 0.83 | PPARG (0.57) | BCHEALOX5PPARGPPARALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2017-02-23 | — | — | US | disclosed |
| US-9458088-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2015-08-27 | — | — | US | disclosed |
| US-9079825-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-8993807-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20150239836-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20150239825-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20170049722-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885DRD2 1753/4885DRD4 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.